Allergan Acquires Topokine Therapeutics

Apr 21, 2016

Allergan has announced that it has acquired Topokine Therapeutics, a Boston-based clinical-stage biotechnology company focused on developing topical medicines for fat reduction.

Under the terms of the agreement, Allergan will pay $85 million upfront, as well as success-based development and sales milestones for XAF5, a first-in-class topical agent in late-stage development for the treatment of steatoblepharon, also known as under-eye bags.

According to Allergan, XAF5 has the potential to be the first topical fat reduction product for the treatment of steatoblepharon, a condition with no current therapeutic options available for patients.

Read the Allergan press release

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments